• Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

  • May 23 2024
  • Duración: 22 m
  • Podcast

Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman Por arte de portada

Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Join Rahul and Rohit Gosain, the Oncology Brothers, in this insightful podcast episode where they discuss the latest advancements in hematology and oncology. In this episode, they are joined by Dr. Mazyar Shadman from Fred Hutch Cancer Center to delve into the Sequoia and Alpine trials that led to the approval of Zanubrutinib in CLL.

    Key Points Discussed:

    · The Sequoia trial focused on Zanubrutinib in first-line CLL treatment, showcasing its superiority over traditional chemotherapy.

    · The Alpine study compared Zanubrutinib to Ibrutinib in relapsed/refractory settings, demonstrating Zanubrutinib's efficacy and safety profile.

    · Acalabrutinib and Zanubrutinib were indirectly compared in a post-analysis, shedding light on their differences.

    · Dr. Shadman provides insights on managing common side effects of Zanubrutinib, highlighting its improved tolerability.

    Tune in to this episode for a comprehensive discussion on Zanubrutinib in CLL, including trial outcomes, comparisons, and practical considerations for patient care. Stay informed with the Oncology Brothers as they navigate the evolving landscape of oncology treatments

    Más Menos
activate_primeday_promo_in_buybox_DT
Enfermedades Físicas Hygiene & Healthy Living
Más Menos

Lo que los oyentes dicen sobre Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles